What is Prolong Pharmaceuticals?
Prolong Pharmaceuticals operates at the intersection of advanced biotechnology and therapeutic innovation, specializing in the development of treatments for complex diseases across CNS, Hematology, and Respiratory domains. The company distinguishes itself through the application of sophisticated PEGylation technology, which optimizes the pharmacokinetic profiles of its drug candidates. Its flagship asset, PP-007, also known as Sanguinate, represents a critical advancement in addressing ischemia and hypoxia in patients suffering from stroke, sickle cell disease, and cystic fibrosis. By targeting the fundamental mechanisms of oxygen delivery to hypoxic tissues, Prolong Pharmaceuticals addresses significant unmet medical needs, positioning itself as a pivotal player in the biopharma landscape.
How much funding has Prolong Pharmaceuticals raised?
Prolong Pharmaceuticals has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in Prolong Pharmaceuticals
PPP
Public-Private Partnership
What's next for Prolong Pharmaceuticals?
With the recent influx of capital, Prolong Pharmaceuticals is well-positioned to accelerate its clinical trial milestones and expand its research capabilities. The strategic focus will likely remain on the commercialization pathway for Sanguinate while simultaneously exploring new applications for its PEGylation platform. As the company transitions from a development-heavy entity to a more mature clinical-stage organization, the emphasis will shift toward regulatory engagement and scaling manufacturing processes to meet potential market demand. This trajectory suggests a robust outlook for the firm as it seeks to redefine standards of care for patients with severe, life-threatening conditions.
See full Prolong Pharmaceuticals company page
